The ANAJIS trial, a small randomised, placebo-controlled trial of anakinra (IL-1 blockade) in patients with sJIA, reported 67% ACR30 response at 1 month compared to 8% of the control group (11). The gene discussed is IL1B; the disease is systemic-onset juvenile idiopathic arthritis.